Our project goals aim at increased survival, improved quality of life and less suffering for cancer patients. Our novel chemical entities (NCE) can prevent over-activation of certain signaling pathways and are based on existing pharmaceuticals that are well tolerable and easy to produce. This will be a first in class drug with little side effects (known drug class), addressing cancer induced cachexia and suppression of the immune system.
We are developing safe and resistance-breaking molecules that target an enzyme essential for nerve signaling in mosquitoes via a new mode of action. In contrast to current insecticides, we have designed our molecules to specifically target mosquitoes, without affecting other organisms.
Acne vulgaris affects more than 80 percent of people at some point in their life and frequently continues into adulthood. Recent data suggest that there are about 650 million people living with acne around the world. This case focuses on a novel approach to fighting acne without the hazards of antibiotic resistance development.
We are developing an oral patch, which will be a patented galenic formulation, providing rapid pain relief for the patient. The product can theoretically reach a target patient population of 10-20,000 patients annually in Sweden, and considerably higher in international markets.
Cyanobacteria have significant potential as industrial biotechnology platforms to produce a wide variety of bio-products, such as polymers, sugars and powerful antioxidants such as C-phycocyanin. Our team have created a set of genetic tools that give significant advantages in the microalgae industry for save, efficient and specific bioproduction.
Current drugs against mycoses are toxic. We aim to develop a new class of antifungal agents that disarm the invasive forms of fungal cells instead of merely eradicating them. This has two advantages: The new compounds are less aggressive for the host and resistance development is reduced.
We are developing a targeted mass-spectrometry biomarker tool for differentiating subgroups of patients with Parkinsonian disorders exhibiting similar clinical symptoms but having distinct molecular etiologies of neurological disease.
Delayed or inappropriate treatment of anaerobic infections may result in severe disease or death. With knowledge levels dropping in clinical laboratories, the need for anaerobic proficiency increase. Dianox is developing educational solutions to halt this trend in health care.